Public health agency the US Food and Drug Administration announced Monday that it has authorised the marketing of Dovato (dolutegravir and lamivudine) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.
The approval of Dovato was awarded to ViiV Healthcare.
Dovato (dolutegravir and lamivudine) is a complete two drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato, added the agency.
This is reportedly the first US FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.
Efficacy and safety of the company's Dovato, one tablet taken daily, was demonstrated in two identical, randomised, double-blind, controlled clinical trials in 1,433 HIV-infected adults with no prior antiretroviral treatment history. The treatment is successful if the patient maintained less than 50 copies/ml of HIV RNA in their blood for at least 48 weeks.
In February 2019, the US Department of Health and Humans Services announced a new initiative, Ending the HIV Epidemic: A Plan for America, a once-in-a-generation opportunity to eliminate new HIV infections in our nation. Approximately 1.1m people in the US are living with HIV.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results